Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
- Published In:
- Diabetes, obesity & metabolism, 25(10), 2805-2814 (2023)
- Authors:
- Saxena, Aditi R, Frias, Juan P(5), Gorman, Donal N, Lopez, Rene N, Andrawis, Nabil, Tsamandouras, Nikolaos, Birnbaum, Morris J
- Database ID:
- RPEP-07351
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-07351APA
Saxena, Aditi R; Frias, Juan P; Gorman, Donal N; Lopez, Rene N; Andrawis, Nabil; Tsamandouras, Nikolaos; Birnbaum, Morris J. (2023). Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.. Diabetes, obesity & metabolism, 25(10), 2805-2814. https://doi.org/10.1111/dom.15168
MLA
Saxena, Aditi R, et al. "Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.." Diabetes, 2023. https://doi.org/10.1111/dom.15168
RethinkPeptides
RethinkPeptides Research Database. "Tolerability, safety and pharmacodynamics of oral, small-mol..." RPEP-07351. Retrieved from https://rethinkpeptides.com/research/saxena-2023-tolerability-safety-and-pharmacodynamics
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.